AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AGENUS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.18+0.14 (+2.32%)
Close on Oct 19, 2026
- Market cap
- $255.47M
- P/E (TTM)
- –
- Dividend yield
- –
AGENUS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member] | $28.15M | $29.15M | – | $29.15M | $24.83M | $23.56M | $25.97M | $24.66M | $22.58M | $27.77M | $53.04M | $20.36M | 81.5% | +13.4% |
| Non-cash royalties [Member] | $28.15M | $29.15M | $31.05M | $29.15M | $24.83M | $23.56M | $25.97M | $24.66M | $22.58M | $27.77M | $53.04M | $20.36M | 81.5% | +13.4% |
| Pre-Commercial Product Revenue [Member] | $6.37M | $4.59M | – | – | $0 | $0 | – | – | – | – | – | – | 18.5% | – |
| Research and Development Revenue [Member] | $0 | – | – | $1.09M | $334.00K | – | $215.00K | $0 | $267.00K | $0 | $30.25M | $3.41M | 0.0% | -100.0% |
| Service Revenue [Member] | $0 | $0 | $0 | $0 | $526.00K | $510.00K | $650.00K | $454.00K | $660.00K | $238.00K | $514.00K | $540.00K | 0.0% | -100.0% |
| Research and development services [Member] | – | – | – | – | – | – | – | – | – | – | $277.00K | $447.00K | – | – |
| Recognition of deferred revenue [Member] | – | – | – | – | – | – | – | – | – | – | – | $2.85M | – | – |
| Other [Member] | – | – | $0 | $0 | $526.00K | $510.00K | $650.00K | $454.00K | $660.00K | $238.00K | $514.00K | $540.00K | – | – |
| Clinical product revenue [Member] | – | – | – | $1.09M | $334.00K | – | $215.00K | $0 | $267.00K | – | $0 | $116.00K | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $34.52M | $33.74M | $34.20M | $30.24M | $25.17M | $23.56M | $26.19M | $24.66M | $22.85M | $27.77M | $83.29M | $23.77M | 100.0% | +37.2% |
| Rest of World [Member] | – | – | $0 | $0 | $526.00K | $510.00K | $650.00K | $454.00K | $660.00K | $238.00K | $514.00K | $540.00K | – | – |
From the segment and revenue-disaggregation notes of Agenus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.